PRICE T ROWE ASSOCIATES INC /MD/ - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$76,677
+197.8%
2,578,199
+80.4%
0.01%
+175.0%
Q2 2023$25,750
+3731.8%
1,428,910
+3319.8%
0.00%
Q1 2023$672
-29.3%
41,783
-19.5%
0.00%
Q4 2022$951
-99.9%
51,931
-15.7%
0.00%
Q3 2022$1,212,000
+19.4%
61,635
+13.3%
0.00%
Q2 2022$1,015,000
+23.0%
54,407
+44.8%
0.00%
Q1 2022$825,000
-62.2%
37,583
-51.1%
0.00%
Q4 2021$2,183,000
+56.7%
76,822
+16.1%
0.00%
Q3 2021$1,393,000
+12.1%
66,163
+0.4%
0.00%
Q2 2021$1,243,000
+66.4%
65,925
+34.9%
0.00%
Q1 2021$747,000
-34.6%
48,865
-39.6%
0.00%
Q4 2020$1,142,000
-15.3%
80,902
-6.0%
0.00%
Q3 2020$1,349,000
-10.5%
86,0680.0%0.00%
Q2 2020$1,508,000
+260.8%
86,068
+203.0%
0.00%
Q1 2020$418,000
-53.9%
28,408
-21.3%
0.00%
Q4 2019$906,000
+15.3%
36,108
-30.9%
0.00%
Q3 2019$786,000
-93.6%
52,283
-89.3%
0.00%
-100.0%
Q2 2019$12,198,000
+10.2%
487,916
+0.4%
0.00%0.0%
Q1 2019$11,064,000
-15.0%
486,130
+12.0%
0.00%0.0%
Q4 2018$13,016,000
+4.7%
433,996
+0.0%
0.00%0.0%
Q3 2018$12,431,000433,9050.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 2,030,616$31,028,0006.04%
5AM Venture Management, LLC 1,362,286$20,816,0003.75%
Burrage Capital Management LLC 272,393$4,162,0003.37%
Altium Capital Management LP 361,930$5,530,0001.54%
Vivo Capital, LLC 2,214,138$33,832,0001.19%
Bain Capital Life Sciences Investors, LLC 1,071,428$16,371,0000.93%
Perceptive Advisors 3,659,381$51,606,0000.65%
New Leaf Venture Partners, L.L.C. 141,000$2,154,0000.50%
DRIEHAUS CAPITAL MANAGEMENT LLC 2,003,688$30,616,0000.45%
Opaleye Management Inc. 188,000$2,873,0000.42%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders